Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs - Wikidata - awgldk - TriplyDB

Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs

Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs

http://www.wikidata.org/entity/Q33344362

about

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2 Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities Gene therapy of carcinoma using ultrasound-targeted microbubble destruction Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.Tumor-induced loss of mural Connexin 43 gap junction activity promotes endothelial proliferation.Redox-active selenium compounds--from toxicity and cell death to cancer treatment Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model Apurinic/apyrimidinic endonuclease 1 regulates angiogenesis in a transforming growth factor β-dependent manner in human osteosarcoma Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.Enhanced inhibition of urinary bladder cancer growth and muscle invasion by allyl isothiocyanate and celecoxib in combination Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI.Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models Is selenium a potential treatment for cancer metastasis?Selenium Induces an Anti-tumor Effect Via Inhibiting Intratumoral Angiogenesis in a Mouse Model of Transplanted Canine Mammary Tumor Cells.Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines.DCE- and DW-MRI as early imaging biomarkers of treatment response in a preclinical model of triple negative breast cancer.Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model.Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.Design and biological characterization of novel cell-penetrating peptides preferentially targeting cell nuclei and subnuclear regions.Extracellular vesicles-mediated signaling in the osteosarcoma microenvironment: Roles and potential therapeutic targets

P2860

Q21261281-728C4F95-FE7D-4D68-9876-C0643357ADDE Q21261285-A82D7E25-C2B1-4EBA-B407-C3B7C30FFBA0 Q26828930-5C5AC981-E899-4ACD-A377-706E1D7348D1 Q30434291-57742CFB-2E9A-41C9-B333-06B749A905FA Q30469815-B22D80BB-D55C-444B-9F70-F537D74AFC6D Q30471456-652E2802-1BAC-4C88-92B6-1857A80F0D03 Q33659462-667BA2D5-0E0B-43E5-A199-5D5F8816F6EF Q33814240-38828BD5-ACA5-4C84-9D6C-C48B2F87187D Q34047866-73A9C5D0-8086-4962-8CB0-3049EB2F9718 Q34849516-9CBD9234-3D7F-43DA-B6D8-3AF10C336A69 Q35034404-AFA76E1D-210F-4017-8E0A-C9F06AC718FA Q35084630-09A63D3B-68CC-4087-8A1D-74247C7676FD Q35243710-964E4D2F-91C1-4FAB-A897-82E5B6B0670D Q35639948-66A4ECE6-4281-45F0-8ADF-FAF0DF651035 Q35658137-0BB9E82F-8DFA-4C5F-B11A-D74960DAFC6F Q35948220-13EF442B-EF9C-4527-8E67-63B4BFC7E6A1 Q36262912-3755BF77-08AE-42FB-82BB-D8E6997D8DA5 Q36653033-52400DEE-992E-42E8-AE8E-7C9C2F99F50D Q36787650-16EF10F6-C5C6-4886-91BA-F3A80740418E Q37169566-9D49D687-A473-4396-B903-7517E4FED726 Q37262189-C7670551-12B8-4B40-93EA-E7013027D8EA Q37314509-D366A149-D093-4AFD-870E-D91FAB214F85 Q37381491-6CBEBDC1-8CDF-459F-B887-6A1B9063E8A8 Q37385796-AD7F5FC6-FD6C-4251-ABCE-5ECA4FBD20E4 Q37681776-1B9D8AD9-8715-4715-AD06-393FE772385B Q38097279-5EBE50E5-792A-47D4-96E7-F105368F8AA3 Q38824373-B5216C02-B472-4A5D-A32E-090F4F518CCD Q39553054-54D074E0-2AE3-48FE-A8A4-411B276719FE Q47670339-FEBED252-3D54-40C7-8842-5C9BB5C34070 Q50050151-67C776F0-12B4-4279-8F40-17A38B8E7430 Q52726721-0C49540F-4E03-4D23-8A39-644520904AA7 Q55435441-1132EB3B-34D8-40C8-BAA4-B399A3B56F75 Q58798664-5C9D30C5-0323-45F9-BA54-F5D2A0ACBB63

P2860

Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs

http://www.wikidata.org/entity/Q33344362

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Tumor vascular maturation and ...... synergy with anticancer drugs

@ast

Tumor vascular maturation and ...... synergy with anticancer drugs

@en

type

label

Tumor vascular maturation and ...... synergy with anticancer drugs

@ast

Tumor vascular maturation and ...... synergy with anticancer drugs

@en

prefLabel

Tumor vascular maturation and ...... synergy with anticancer drugs

@ast

Tumor vascular maturation and ...... synergy with anticancer drugs

@en

P1433

Q33344362-0EE7C908-9CB1-4A8F-A5E6-920A15FA8B5F

P1476

Q33344362-7130AE21-3366-46A3-AE71-808CF5C3C7C6

P2093

Q33344362-59BEB71B-F896-425D-9E07-9C8B9456108D

Q33344362-6F3ABFA5-9B5A-40DB-A737-E4E6102ADF41

Q33344362-94FD496B-BEC1-485D-96F1-21D61BF80F1A

Q33344362-C4430425-90A8-4FA0-B12A-E743929D37A6

Q33344362-CC825779-9426-4D83-823A-2AC656D78AB9

Q33344362-D362E1F3-5495-4923-B215-8509A0F8FAF9

P2860

Q33344362-12A9CFAE-FD4C-40E2-A789-8FF162157B55

Q33344362-1BAB4D10-D2E7-420C-9C21-6A60C7B42363

Q33344362-1D7BC6F5-D542-4D9A-976A-CFC73767249F

Q33344362-273AEC53-6F85-4116-9BF9-7A90D281245C

Q33344362-2FF3ADD9-C3D7-4F22-BA58-0D7D2EA69B65

Q33344362-34605B0E-EB7C-42A4-AE17-232849C2681A

Q33344362-3BED56F5-CF5A-4417-B68F-959FB4E542EC

Q33344362-4A4006DA-CB07-44F2-89C4-AB6B80DA50B9

Q33344362-587E41A4-A079-4D65-A6ED-6BE77C0C610B

Q33344362-5FEAD970-AD18-4C8F-91EC-3A1BF7318AAF

P304

Q33344362-8CD0D158-FC1E-47CF-A24B-2095BD0544D0

P31

Q33344362-7DBD0D1E-1B84-419B-8AC7-683545AE8055

P356

Q33344362-7C6D6954-1201-4DAC-A9D3-F3D0AB9342D2

P407

Q33344362-C2D0FB46-CCA9-489D-ADEC-74DA6440BABC

P433

Q33344362-9B3BA489-BA54-47C6-BAC7-5A82D468A914

P478

Q33344362-2BD05397-117C-45C8-BA7D-2B75B52D1279

P577

Q33344362-315C671B-EFCB-4D1E-B2E8-5BC63629877E

P5875

Q33344362-D67943C1-1651-40B6-B3DC-1C5742373F78

P698

Q33344362-AE5CFA41-E2E0-49CF-8084-6A0473F6BBAE

P921

Q33344362-B0DAB41F-7561-4031-8FFE-809CED1126A7

P932

Q33344362-FEA80803-9546-45DF-81AE-565EDAD8E662

P356

1078-0432.CCR-08-0212

P1433

Clinical Cancer Research

P1476

Tumor vascular maturation and ...... synergy with anticancer drugs

@en

P2093

Arup Bhattacharya

http://www.w3.org/2001/XMLSchema#string

Károly Tóth

http://www.w3.org/2001/XMLSchema#string

Mary M Vaughan

http://www.w3.org/2001/XMLSchema#string

Mukund Seshadri

http://www.w3.org/2001/XMLSchema#string

Steven D Oven

http://www.w3.org/2001/XMLSchema#string

Youcef M Rustum

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Specialization of tumour vasculature.

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Angiogenesis modulation in cancer research: novel clinical approaches.

Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts

Use of a carbocyanine dye as a marker of functional vasculature in murine tumours

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.

A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

P304

3926-3932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0212

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5296349

http://www.w3.org/2001/XMLSchema#string

P698

18559614

http://www.w3.org/2001/XMLSchema#string

P921

P932

2504718

http://www.w3.org/2001/XMLSchema#string